Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML.

Guardia RD, González-Silva L, López-Millán B, Rodríguez-Sevilla JJ, Baroni ML, Bueno C, Anguita E, Vives S, Palomo L, Lapillonne H, Varela I, Menendez P.

Genes (Basel). 2020 Jan 9;11(1). pii: E73. doi: 10.3390/genes11010073.

2.

Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial.

Petit A, Ducassou S, Leblanc T, Pasquet M, Rousseau A, Ragu C, Cachanado M, Nelken B, Bertrand Y, Michel G, Gandemer V, Cuccuini W, Fenneteau O, Lapillonne H, Auvrignon A, Baruchel A, Leverger G.

Hemasphere. 2018 Nov 29;2(6):e159. doi: 10.1097/HS9.0000000000000159. eCollection 2018 Dec.

3.

Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.

Lopez CK, Noguera E, Stavropoulou V, Robert E, Aid Z, Ballerini P, Bilhou-Nabera C, Lapillonne H, Boudia F, Thirant C, Fagnan A, Arcangeli ML, Kinston SJ, Diop M, Job B, Lecluse Y, Brunet E, Babin L, Villeval JL, Delabesse E, Peters AHFM, Vainchenker W, Gaudry M, Masetti R, Locatelli F, Malinge S, Nerlov C, Droin N, Lobry C, Godin I, Bernard OA, Göttgens B, Petit A, Pflumio F, Schwaller J, Mercher T.

Cancer Discov. 2019 Dec;9(12):1736-1753. doi: 10.1158/2159-8290.CD-18-1463. Epub 2019 Oct 29.

PMID:
31662298
4.

Leukemia Cutis in Childhood Acute Myeloid Leukemia: Epidemiological, Clinical, Biological, and Prognostic Characteristics of Patients Included in the ELAM02 Study.

Gouache E, Greze V, Strullu M, Saultier P, Fenneteau O, Gandemer V, Ragu C, Auvrignon A, Boutroux H, Lapillonne H, Pasquet M, Leverger G.

Hemasphere. 2018 Oct;2(5):e141. doi: 10.1097/HS9.0000000000000141. Epub 2018 Oct 2. No abstract available.

5.

The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Villenet C, Petit A, Rousseau A, Ng SWK, Paquet A, Gonzales F, Barthélémy A, Leprêtre F, Pottier N, Nelken B, Michel G, Baruchel A, Bertrand Y, Leverger G, Lapillonne H, Figeac M, Dick JE, Wang JCY, Preudhomme C, Cheok M.

Leukemia. 2019 Feb;33(2):348-357. doi: 10.1038/s41375-018-0227-5. Epub 2018 Aug 8.

PMID:
30089916
6.

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.

Bond J, Labis E, Marceau-Renaut A, Duployez N, Labopin M, Hypolite G, Michel G, Ducassou S, Boutroux H, Nelken B, Bertrand Y, Baruchel A, Petit A, Asnafi V, Leverger G, Preudhomme C, Macintyre E, Lapillonne H.

Leukemia. 2018 Aug;32(8):1878-1882. doi: 10.1038/s41375-018-0187-9. Epub 2018 Jun 27. No abstract available.

PMID:
29950694
7.

Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia.

Itzykson R, Duployez N, Fasan A, Decool G, Marceau-Renaut A, Meggendorfer M, Jourdan E, Petit A, Lapillonne H, Micol JB, Cornillet-Lefebvre P, Ifrah N, Leverger G, Dombret H, Boissel N, Haferlach T, Preudhomme C.

Blood. 2018 Jul 12;132(2):187-196. doi: 10.1182/blood-2018-03-837781. Epub 2018 Apr 24.

PMID:
29692343
8.

SNP-array lesions in core binding factor acute myeloid leukemia.

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Oncotarget. 2018 Jan 8;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

9.

Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group.

Marceau-Renaut A, Duployez N, Ducourneau B, Labopin M, Petit A, Rousseau A, Geffroy S, Bucci M, Cuccuini W, Fenneteau O, Ruminy P, Nelken B, Ducassou S, Gandemer V, Leblanc T, Michel G, Bertrand Y, Baruchel A, Leverger G, Preudhomme C, Lapillonne H.

Hemasphere. 2018 Feb 21;2(1):e31. doi: 10.1097/HS9.0000000000000031. eCollection 2018 Jan-Feb.

10.

Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial.

Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G.

Pediatr Hematol Oncol. 2017 Nov;34(8):425-427. doi: 10.1080/08880018.2017.1414905. Epub 2018 Jan 5.

PMID:
29303660
11.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.

Petit A, Trinquand A, Chevret S, Ballerini P, Cayuela JM, Grardel N, Touzart A, Brethon B, Lapillonne H, Schmitt C, Thouvenin S, Michel G, Preudhomme C, Soulier J, Landman-Parker J, Leverger G, Macintyre E, Baruchel A, Asnafi V; French Acute Lymphoblastic Leukemia Study Group (FRALLE).

Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19.

PMID:
29051182
12.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

13.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

Héritier S, Hélias-Rodzewicz Z, Lapillonne H, Terrones N, Garrigou S, Normand C, Barkaoui MA, Miron J, Plat G, Aladjidi N, Pagnier A, Deville A, Gillibert-Yvert M, Moshous D, Lefèvre-Utile A, Lutun A, Paillard C, Thomas C, Jeziorski E, Nizard P, Taly V, Emile JF, Donadieu J.

Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.

PMID:
28444728
14.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, Lapillonne H, Renneville A, Ragu C, Figeac M, Celli-Lebras K, Lacombe C, Micol JB, Abdel-Wahab O, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.

Blood. 2016 May 19;127(20):2451-9. doi: 10.1182/blood-2015-12-688705. Epub 2016 Mar 15.

15.

Childhood diagnosis of genetic thrombocytopenia with mutation in the ankyrine repeat domain 26 gene.

Boutroux H, Petit A, Auvrignon A, Lapillonne H, Ballerini P, Favier R, Leverger G.

Eur J Pediatr. 2015 Oct;174(10):1399-403. doi: 10.1007/s00431-015-2549-x. Epub 2015 Apr 24.

PMID:
25902755
16.

Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21).

Duployez N, Micol JB, Boissel N, Petit A, Geffroy S, Bucci M, Lapillonne H, Renneville A, Leverger G, Ifrah N, Dombret H, Abdel-Wahab O, Jourdan E, Preudhomme C.

Leuk Lymphoma. 2016;57(1):199-200. doi: 10.3109/10428194.2015.1037754. Epub 2015 May 15. No abstract available.

PMID:
25856206
17.

Molecular signature of erythroblast enucleation in human embryonic stem cells.

Rouzbeh S, Kobari L, Cambot M, Mazurier C, Hebert N, Faussat AM, Durand C, Douay L, Lapillonne H.

Stem Cells. 2015 Aug;33(8):2431-41. doi: 10.1002/stem.2027. Epub 2015 May 13.

18.

Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French Severe Congenital Neutropenia Registry.

Desplantes C, Fremond ML, Beaupain B, Harousseau JL, Buzyn A, Pellier I, Roques G, Morville P, Paillard C, Bruneau J, Pinson L, Jeziorski E, Vannier JP, Picard C, Bellanger F, Romero N, de Pontual L, Lapillonne H, Lutz P, Chantelot CB, Donadieu J.

Orphanet J Rare Dis. 2014 Dec 10;9:183. doi: 10.1186/s13023-014-0183-8.

19.

Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-κB pathway activation but not with poor prognosis.

Poglio S, Cahu X, Uzan B, Besnard-Guérin C, Lapillonne H, Leblanc T, Baruchel A, Landman-Parker J, Petit A, Baleydier F, Amsellem S, Baud V, Ballerini P, Pflumio F.

Leukemia. 2015 Apr;29(4):977-80. doi: 10.1038/leu.2014.317. Epub 2014 Nov 5. No abstract available.

PMID:
25371179
20.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E.

Blood. 2014 Aug 28;124(9):1445-9. doi: 10.1182/blood-2014-04-571018. Epub 2014 Jun 27.

21.

SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.

Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, Lapillonne H, Deswarte C, Goussard P, Laurendeau I, Uzan B, Pflumio F, Brizard F, Vabres P, Naguibvena I, Fasola S, Millot F, Porteu F, Vidaud D, Landman-Parker J, Ballerini P.

Oncogene. 2015 Jan 29;34(5):631-8. doi: 10.1038/onc.2013.587. Epub 2014 Jan 27.

PMID:
24469042
22.

Human induced pluripotent stem cells can reach complete terminal maturation: in vivo and in vitro evidence in the erythropoietic differentiation model.

Kobari L, Yates F, Oudrhiri N, Francina A, Kiger L, Mazurier C, Rouzbeh S, El-Nemer W, Hebert N, Giarratana MC, François S, Chapel A, Lapillonne H, Luton D, Bennaceur-Griscelli A, Douay L.

Haematologica. 2012 Dec;97(12):1795-803. doi: 10.3324/haematol.2011.055566. Epub 2012 Jun 24.

23.

RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation.

Ballerini P, Struski S, Cresson C, Prade N, Toujani S, Deswarte C, Dobbelstein S, Petit A, Lapillonne H, Gautier EF, Demur C, Lippert E, Pages P, Mansat-De Mas V, Donadieu J, Huguet F, Dastugue N, Broccardo C, Perot C, Delabesse E.

Leukemia. 2012 Nov;26(11):2384-9. doi: 10.1038/leu.2012.109. Epub 2012 Apr 19.

PMID:
22513837
24.

Human fetal liver: an in vitro model of erythropoiesis.

Pourcher G, Mazurier C, King YY, Giarratana MC, Kobari L, Boehm D, Douay L, Lapillonne H.

Stem Cells Int. 2011;2011:405429. doi: 10.4061/2011/405429. Epub 2011 Sep 22.

25.

Proof of principle for transfusion of in vitro-generated red blood cells.

Giarratana MC, Rouard H, Dumont A, Kiger L, Safeukui I, Le Pennec PY, François S, Trugnan G, Peyrard T, Marie T, Jolly S, Hebert N, Mazurier C, Mario N, Harmand L, Lapillonne H, Devaux JY, Douay L.

Blood. 2011 Nov 10;118(19):5071-9. doi: 10.1182/blood-2011-06-362038. Epub 2011 Sep 1.

26.

Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.

Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T.

Nephrol Dial Transplant. 2012 Mar;27(3):1083-9. doi: 10.1093/ndt/gfr405. Epub 2011 Aug 1.

PMID:
21810762
27.

Red blood cells from induced pluripotent stem cells: hurdles and developments.

Mazurier C, Douay L, Lapillonne H.

Curr Opin Hematol. 2011 Jul;18(4):249-53. doi: 10.1097/MOH.0b013e3283476129. Review.

PMID:
21519239
28.

Banking of pluripotent adult stem cells as an unlimited source for red blood cell production: potential applications for alloimmunized patients and rare blood challenges.

Peyrard T, Bardiaux L, Krause C, Kobari L, Lapillonne H, Andreu G, Douay L.

Transfus Med Rev. 2011 Jul;25(3):206-16. doi: 10.1016/j.tmrv.2011.01.002. Epub 2011 Mar 4. Review.

PMID:
21377319
29.

A cytometric study of the red blood cells in Gaucher disease reveals their abnormal shape that may be involved in increased erythrophagocytosis.

Bratosin D, Tissier JP, Lapillonne H, Hermine O, de Villemeur TB, Cotoraci C, Montreuil J, Mignot C.

Cytometry B Clin Cytom. 2011 Jan;80(1):28-37. doi: 10.1002/cyto.b.20539.

30.

Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine.

Lapillonne H, Kobari L, Mazurier C, Tropel P, Giarratana MC, Zanella-Cleon I, Kiger L, Wattenhofer-Donzé M, Puccio H, Hebert N, Francina A, Andreu G, Viville S, Douay L.

Haematologica. 2010 Oct;95(10):1651-9. doi: 10.3324/haematol.2010.023556. Epub 2010 May 21.

31.

Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.

Garderet L, Kobari L, Mazurier C, De Witte C, Giarratana MC, Pérot C, Gorin NC, Lapillonne H, Douay L.

Haematologica. 2010 Mar;95(3):398-405. doi: 10.3324/haematol.2009.012773. Epub 2009 Oct 8.

32.

Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia.

Lapillonne H, Llopis L, Auvrignon A, Renneville A, Labopin M, Mazingue F, Perot C, Lai JL, Philippe N, Ballerini P, Zurawski V, Adam M, Douay L, Leverger G, Landman-Parker J, Preudhomme C.

Leukemia. 2010 Jan;24(1):205-9. doi: 10.1038/leu.2009.172. Epub 2009 Sep 17. No abstract available.

PMID:
19759559
33.

SPRED1 disorder and predisposition to leukemia in children.

Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J.

Blood. 2009 Jul 30;114(5):1131. doi: 10.1182/blood-2009-04-218503. No abstract available.

PMID:
19643996
34.

Stem cells--a source of adult red blood cells for transfusion purposes: present and future.

Douay L, Lapillonne H, Turhan AG.

Crit Care Clin. 2009 Apr;25(2):383-98, Table of Contents. doi: 10.1016/j.ccc.2008.12.008. Review.

PMID:
19341915
35.

Stem cell mobilization in idiopathic steroid-sensitive nephrotic syndrome.

Lapillonne H, Leclerc A, Ulinski T, Balu L, Garnier A, Dereuddre-Bosquet N, Watier H, Schlageter MH, Deschênes G.

Pediatr Nephrol. 2008 Aug;23(8):1251-6. doi: 10.1007/s00467-008-0793-2. Epub 2008 May 6.

PMID:
18458957
36.

Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy.

Lhermitte L, de Labarthe A, Dupret C, Lapillonne H, Millien C, Landman-Parker J, Hermine O, Baruchel A, Sigaux F, Macintyre E, Asnafi V.

Leukemia. 2006 Oct;20(10):1908-10. Epub 2006 Aug 10. No abstract available.

PMID:
16900212
37.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai JL, Ballerini P, Mazingue F, Fasola S, Dehée A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J.

J Clin Oncol. 2006 Apr 1;24(10):1507-15.

PMID:
16575000
38.

Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.

Brethon B, Auvrignon A, Cayuela JM, Lapillonne H, Leverger G, Baruchel A.

Haematologica. 2006 Mar;91(3):419-21.

39.

NUP214-ABL1 amplification in t(5;14)/HOX11L2-positive ALL present with several forms and may have a prognostic significance.

Ballerini P, Busson M, Fasola S, van den Akker J, Lapillonne H, Romana SP, Marynen P, Bernard OA, Landman-Parker J, Berger R.

Leukemia. 2005 Mar;19(3):468-70. No abstract available.

PMID:
15674415
40.

Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells.

Giarratana MC, Kobari L, Lapillonne H, Chalmers D, Kiger L, Cynober T, Marden MC, Wajcman H, Douay L.

Nat Biotechnol. 2005 Jan;23(1):69-74. Epub 2004 Dec 26.

PMID:
15619619
41.
42.

Influence of dietary cholesterol on vitamin d metabolism in formula-fed preterm neonates.

Picaud JC, Boucher P, Lapillonne A, Berthouze M, Delvin E, Boehm G, Claris O, Laborie S, Reygrobellet B, Lapillonne H, Glorieux FH, Salle BL.

J Pediatr Gastroenterol Nutr. 2002 Aug;35(2):180-4.

PMID:
12187294
43.

TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development.

Gingras MC, Lapillonne H, Margolin JF.

Mol Immunol. 2002 Mar;38(11):817-24.

PMID:
11922939
44.

Analysis of the cell cycle in mouse embryonic stem cells.

Savatier P, Lapillonne H, Jirmanova L, Vitelli L, Samarut J.

Methods Mol Biol. 2002;185:27-33. Review. No abstract available.

PMID:
11768996
45.

CFFM4: a new member of the CD20/FcepsilonRIbeta family.

Gingras MC, Lapillonne H, Margolin JF.

Immunogenetics. 2001 Aug;53(6):468-76.

PMID:
11685457
46.

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D, Konopleva M, Zhao S, Estey E, Andreeff M.

J Clin Invest. 2001 Sep;108(6):851-9.

47.

Duration of pregnancy and risk of breast cancer.

Lapillonne H, Golsteyn RM, Lapillonne A.

Lancet. 1999 Jun 12;353(9169):2075. No abstract available.

PMID:
10376653
48.

Supplemental Content

Loading ...
Support Center